HomeACADEMIA
ACADEMIA

Gastric Cancer Guidelines Likely to Recommend Opdivo in 3rd Line Settings
(Apr.24.2017)

New Japanese gastric cancer guidelines due out this summer are expected to recommend Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) as a third-line regimen alongside irinotecan, according to Narikazu Boku, a gastrointestinal oncologist at the National Cancer Center Hospital ...
(LOG IN FOR FULL STORY)

News Calendar